Alpha Teknova (NASDAQ:TKNO) Sets New 1-Year High – Should You Buy?

Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) reached a new 52-week high during trading on Tuesday . The stock traded as high as $9.72 and last traded at $9.45, with a volume of 208104 shares traded. The stock had previously closed at $7.68.

Alpha Teknova Trading Up 21.6 %

The company has a quick ratio of 3.94, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The company’s fifty day moving average price is $7.18 and its two-hundred day moving average price is $4.76. The firm has a market cap of $497.90 million, a PE ratio of -12.62 and a beta of 0.37.

Alpha Teknova (NASDAQ:TKNO) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.04). The business had revenue of $9.58 million during the quarter, compared to analysts’ expectations of $9.30 million. Alpha Teknova had a negative net margin of 87.17% and a negative return on equity of 35.30%. During the same period in the prior year, the firm posted ($0.34) EPS. As a group, sell-side analysts forecast that Alpha Teknova, Inc. will post -0.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpha Teknova

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. State Street Corp grew its stake in shares of Alpha Teknova by 249.3% during the 3rd quarter. State Street Corp now owns 76,645 shares of the company’s stock worth $371,000 after purchasing an additional 54,700 shares during the period. Geode Capital Management LLC boosted its holdings in Alpha Teknova by 24.4% during the third quarter. Geode Capital Management LLC now owns 188,173 shares of the company’s stock worth $911,000 after buying an additional 36,914 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Alpha Teknova during the third quarter worth about $1,483,000. Finally, Roubaix Capital LLC purchased a new position in Alpha Teknova in the third quarter valued at about $2,015,000. Institutional investors and hedge funds own 13.81% of the company’s stock.

Alpha Teknova Company Profile

Alpha Teknova, Inc produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.